Jeito Capital’s New Fund Raises $1.2 Billion for Biopharma Bets

Jeito Capital, a biopharma-focused private equity firm, has raised $1.2 billion for its latest fund to deploy money into clinical-stage companies in Europe, tapping into increased investor interest from the US.

Jeito II exceeded its initial target and tripled the private equity firm’s assets to €1.6 billion ($1.8 billion), according to a statement reviewed by Bloomberg. The predecessor vehicle, which closed in 2021, raised €534 million.

“In 20-plus years of fundraising, at Jeito and before, I’ve never seen this level of interest from US investors in Europe,” Rafaèle Tordjman, founder and chief executive officer of Paris-based Jeito Capital, ...